# US 2026/0294957 A1 · Therapeutic circular dna forms

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0294957 A1
- Document ID: US20260294957A1
- Status: Published application
- Kind: A1
- Application number: 19/703,449
- Filed: 2026-06-10
- Published: 2026-10-01
- Earliest claimed: 2024-06-26
- Assignees: Flagship Pioneering Innovations Vii, LLC
- Applicants: Flagship Pioneering Innovations Vii, LLC
- Inventors: Edward Matthew Kennedy; Camilo Ayala Breton; Carl Wayne Brown, III; Brian Patrick Mead
- Web page: https://patentgrep.com/patent/US20260294957A1

## CPC

- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 38/1774: {Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)}
- A61K 48/0033: {the non-active part being non-polymeric}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- C07H 21/04: with deoxyribosyl as saccharide radical
- C12N 9/1252: {DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase}
- C12N 9/16: acting on ester bonds (3.1)
- C12N 9/93: {Ligases (6)}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12P 19/34: Polynucleotides, e.g. nucleic acids, oligoribonucleotides
- C12Y 207/07007: DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
- C12Y 301/21: Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C12Y: ENZYMES

## Abstract

The disclosure provides, for example, double stranded DNA (dsDNA) molecules comprising one or more chemically modified nucleobases. In some embodiments, the dsDNA molecule is circular and comprises a first strand and a second strand, wherein the first strand comprises one or more chemically modified nucleobases, and the second strand is free of chemically modified nucleobases. In some embodiments, the dsDNA molecule comprises a promoter sequence and an effector sequence that encodes an effector.

## Claims

### Claim 1

A pharmaceutical composition comprising a carrier that comprises a double stranded DNA (dsDNA) molecule, wherein:
(a) the dsDNA molecule is circular;
(b) the dsDNA molecule comprises a first strand and a second strand, wherein:
at least 25% of thymine or uracil positions in the first strand of the dsDNA molecule comprise a uracil nucleobase, and
the second strand is free of chemically modified nucleobases; and
(c) the dsDNA molecule comprises an effector sequence that encodes an effector.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the first strand is a sense strand and the second strand is an antisense strand.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein the first strand is an antisense strand and the second strand is a sense strand.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein the dsDNA molecule further comprises a promoter sequence operably linked to the effector sequence.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, wherein the effector is selected from the group consisting of: a transcription factor, a chromatin remodeling factor, an antigen, a peptide, a hormone, an enzyme, an antibody, a receptor ligand, a receptor, a clotting factor, and a membrane protein.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein the effector is a chimeric antigen receptor (CAR) or a T cell receptor.

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, wherein the uracil nucleobase is a canonical uracil nucleobase.

### Claim 8 (depends on 1)

The pharmaceutical composition of claim 1, wherein the uracil nucleobase is a chemically modified uracil nucleobase.

### Claim 9 (depends on 1)

The pharmaceutical composition of claim 1, wherein at least 50% of thymine or uracil positions in the first strand of the dsDNA molecule comprise a uracil nucleobase.

### Claim 10 (depends on 1)

The pharmaceutical composition of claim 1, wherein at least 75% of thymine or uracil positions in the first strand of the dsDNA molecule comprise a uracil nucleobase.

### Claim 11 (depends on 1)

The pharmaceutical composition of claim 1, wherein at least 90% of thymine or uracil positions in the first strand of the dsDNA molecule comprise a uracil nucleobase.

### Claim 12 (depends on 1)

The pharmaceutical composition of claim 1, wherein the dsDNA molecule has a length of between 500-1000, 1000-2000, 2000-3000, 3000-4000, or 4000-5000 nucleotides.

### Claim 13 (depends on 1)

The pharmaceutical composition of claim 1, wherein the dsDNA molecule further comprises one or more additional chemically modified nucleotides that comprise a backbone modification or a chemically modified sugar.

### Claim 14 (depends on 1)

The pharmaceutical composition of claim 1, wherein the first strand of the dsDNA molecule further comprises a second type of chemically modified nucleobase.

### Claim 15 (depends on 1)

The pharmaceutical composition of claim 1, wherein at least 99% of sugars of the dsDNA molecule are deoxyribose sugars.

### Claim 16 (depends on 1)

The pharmaceutical composition of claim 1, wherein the longest stretch of unmodified nucleotides in the first strand is no more than 100 nucleotides.

### Claim 17 (depends on 1)

The pharmaceutical composition of claim 1, wherein the dsDNA molecule is resistant to endonuclease digestion.

### Claim 18 (depends on 1)

The pharmaceutical composition of claim 1, wherein the effector is a protein, and wherein when the dsDNA molecule is introduced to a cell, the cell exhibits a level of the protein that is at least 80% of the level of the protein in a control cell of the same type that was contacted with an unmodified circular dsDNA molecule having the same sequence as the dsDNA molecule but comprising no chemically modified nucleobases.

### Claim 19 (depends on 1)

The pharmaceutical composition of claim 1, wherein when the dsDNA molecule is contacted to a human cell, the cell exhibits a level of cyclic AMP-GMP (cGAMP) that is less than 10% of the level of cGAMP in a control cell of the same type that was contacted with an unmodified circular dsDNA molecule having the same sequence as the dsDNA molecule but comprising no chemically modified nucleobases.

### Claim 20 (depends on 1)

The pharmaceutical composition of claim 1, wherein at least 70% by mass of total DNA in the composition is the dsDNA molecule, and/or the pharmaceutical composition is free of one or more of: endotoxin, mononucleotides, and protein.

### Claim 21 (depends on 1)

The pharmaceutical composition of claim 1, which further comprises a protein or a second nucleic acid molecule encoding the protein.

### Claim 22 (depends on 21)

The pharmaceutical composition of claim 21, wherein the protein is an enzyme, a DNA-binding protein, an RNA-binding protein, a nuclear protein, a cytoplasmic protein, a kinase, a phosphatase, a structural protein, an antigen, or an antibody.

### Claim 23 (depends on 1)

The pharmaceutical composition of claim 1, wherein the carrier is a nanoparticle.

### Claim 24 (depends on 1)

A method of delivering an effector to a target cell or a subject in need thereof, the method comprising:
contacting the target cell with or administering to the subject the pharmaceutical composition of claim 1,
thereby delivering the effector to the target cell or the subject.

### Claim 25 (depends on 1)

A method of treating a cell, tissue, or subject in need thereof, the method comprising:
administering to the cell, tissue, or subject the pharmaceutical composition of claim 1;
thereby treating the cell, tissue, or subject.

### Claim 26

A dsDNA molecule, wherein:
(a) the dsDNA molecule is circular;
(b) the dsDNA molecule comprises a first strand and a second strand, wherein:
at least 25% of thymine or uracil positions in the first strand of the dsDNA molecule comprise a uracil nucleobase, and
the second strand is free of chemically modified nucleobases; and
(c) the dsDNA molecule comprises an effector sequence that encodes an effector.

### Claim 27

A dsDNA molecule, wherein:
(a) the dsDNA molecule is circular;
(b) the dsDNA molecule comprises a first strand and a second strand, wherein:
the first strand comprises one or more chemically modified nucleobases, wherein the chemically modified nucleobase is a chemically modified cytosine nucleobase or a chemically modified guanine nucleobase, and
the second strand is substantially free of chemically modified nucleobases.

### Claim 28

A dsDNA molecule, comprising:
a promoter region that comprises: i) a bidirectional promoter sequence, or ii) a first promoter sequence and a second promoter sequence that are oriented to drive transcription in opposite directions,
a first effector sequence situated on one side of the promoter region, wherein the first effector sequence has a first strand that comprises one or more chemically modified nucleobases, and a second strand that is substantially free of chemically modified nucleobases, and wherein the first effector sequence encodes a first effector; and
a second effector sequence situated on the other side of the promoter region, wherein the second effector sequence has a first strand that comprises one or more chemically modified nucleobases, and a second strand that is substantially free of chemically modified nucleobases, and wherein the second effector sequence encodes a second effector; and
wherein the bidirectional promoter sequence is operably linked to the first effector sequence and the second effector sequence, or wherein the first promoter sequence is operably linked to the first effector sequence and the second promoter sequence is operably linked to the second effector sequence.

### Claim 29 (depends on 28)

A method of delivering a first effector and a second effector to a target cell or a subject in need thereof, the method comprising:
contacting the target cell with or administering to the subject the dsDNA molecule of claim 28,
thereby delivering the first effector and the second effector to the target cell or the subject.

### Claim 30 (depends on 28)

A method of treating a cell, tissue, or subject in need thereof, the method comprising:
administering to the cell, tissue, or subject the dsDNA molecule of claim 28;
thereby treating the cell, tissue, or subject.
